Inflammation and atherosclerosis

Herz

Volumn 29, Issue 8, 2004, Pages 741-748

  Steffens, Sabine ^a   Mach, François ^a  

^a UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Atherosclerosis; Chronic inflammation; Clinical markers; Statins

Indexed keywords

CD40 ANTIGEN; CD40 LIGAND; CELL ADHESION MOLECULE; CHEMOKINE; CYTOKINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; DENDRITIC CELL; DISEASE COURSE; GAP JUNCTION; HUMAN; IMMUNE RESPONSE; INFLAMMATION; MEDICAL RESEARCH; MONOCYTE; RISK FACTOR; SMOOTH MUSCLE FIBER; T LYMPHOCYTE;

ANIMALS; ARTERIOSCLEROSIS; BIOLOGICAL MARKERS; HUMANS; MODELS, IMMUNOLOGICAL; RISK ASSESSMENT; RISK FACTORS; VASCULITIS;

EID: 12344328181     PISSN: 03409937     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00059-004-2634-9     Document Type: Article

References (83)

1. Libby P. Inflammation in atherosclerosis. Nature 2002;420:868-74.
2. Lusis AJ. Atherosclerosis. Nature 2000;407:233-41.
3. Glass CK, Witztum JL. Atherosclerosis, the road ahead. Cell 2001;104:503-16.
4. Willerson JT, Ridker PM. Inflammation as a cardiovascular risk factor. Circulation 2004;109:112-10.
5. Blake GJ, Ridker PM. Novel clinical markers of vascular wall inflammation. Circ Res 2001;89:763-71.
6. Breslow JL. Mouse models of atherosclerosis. Science 1996;272: 685-8.
7. Assmann G, Cullen P, Jossa F, et al. Coronary heart disease: reducing the risk: the scientific background to primary and secondary prevention of coronary heart disease. A world wide view. International Task Force for the Prevention of Coronary Heart Disease. Arterioscler Thromb Vasc Biol 1999;19:1819-24.
8. Navab M, Berliner JA, Watson AD, et al. The yin and yang of oxidation in the development of the fatty streak. A review based on the 1994 George Lyman Duff Memorial Lecture. Arterioscler Thromb Vasc Biol 1996;16:831-42.
9. Vora DK, Fang ZT, Liva SM, et al. Induction of P-selectin by oxidized lipoproteins. Separate effects on synthesis and surface expression. Circ Res 1997;80:810-8.
10. Watson AD, Leitinger N, Navab M, et al. Structural identification by mass spectrometry of oxidized phospholipids in minimally oxidized low density lipoprotein that induce monocyte/endothelial interactions and evidence for their presence in vivo. J Biol Chem 1997;272:13597-607.
11. Maier JA, Barenghi L, Bradamante S, et al. Induction of human endothelial cell growth by mildly oxidized low density lipoprotein. Atherosclerosis 1996;123:115-21.
12. Wang GP, Deng ZD, Ni J, et al. Oxidized low density lipoprotein and very low density lipoprotein enhance expression of monocyte chemoattractant protein-1 in rabbit peritoneal exudate macrophages. Atherosclerosis 1997;133:31-6.
13. Aikawa M, Sugiyama S, Hill CC, et al. Lipid lowering reduces oxidative stress and endothelial cell activation in rabbit atheroma. Circulation 2002;106:1390-6.
14. Heinecke JW. Oxidants and antioxidants in the pathogenesis of atherosclerosis: implications for the oxidized low density lipoprotein hypothesis. Atherosclerosis 1998;141:1-15.
15. Knowles JW, Reddick RL, Jennette JC, et al. Enhanced atherosclerosis and kidney dysfunction in eNOS(-/-)Apoe(-/-) mice are ameliorated by enalapril treatment. J Clin Invest 2000;105:451-8.
16. Detmers PA, Hernandez M, Mudgett J, et al. Deficiency in inducible nitric oxide synthase results in reduced atherosclerosis in apolipoprotein E-deficient mice. J Immunol 2000;165:3430-5.
17. Libby P, Egan D, Skarlatos S. Roles of infectious agents in atherosclerosis and restenosis: an assessment of the evidence and need for future research. Circulation 1997;96:4095-103.
18. Steinberg D, Parthasarathy S, Carew TE, et al. Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med 1989;320:915-24.
19. Daugherty A, Rateri DL. T lymphocytes in atherosclerosis: the yin-yang of Thi and Th2 influence on lesion formation. Circ Res 2002;90:1039-40.
20. Benagiano M, Azzurri A, Ciervo A, et al. T helper type 1 lymphocytes drive inflammation in human atherosclerotic lesions. Proc Natl Acad Sci U S A 2003;100:6658-63.
21. Hansson GK. Immune mechanisms in atherosclerosis. Arterioscler Thromb Vasc Biol 2001;21:1876-90.
22. Mallat Z, Gojova A, Brun V, et al. Induction of a regulatory T cell type 1 response reduces the development of atherosclerosis in apolipoprotein E-knockout mice. Circulation 2003;108:1232-7.
23. Raines EW, Ross R. Smooth muscle cells and the pathogenesis of the lesions of atherosclerosis. Br Heart J 1993;69:S30-7.
24. Yu X, Dluz S, Graves DT, et al. Elevated expression of monocyte chemoattractant protein by vascular smooth muscle cells in hypercholesterolemic primates. Proc Natl Acad Sci USA 1992;89:6953-7.
25. Nelken NA, Coughlin SR, Gordon D, et al. Monocyte chemoattractant protein-i in human atheromatous plaques. J Clin Invest 1991;88:1121-7.
26. Bobryshev YV, Lord RS. Ultrastructural recognition of cells with dendritic cell morphology in human aortic intima. Contacting interactions of vascular dendritic cells in athero-resistant and athero-prone areas of the normal aorta. Arch Histol Cytol 1995;58:307-22.
27. Bobryshev YV, Lord RS. S-100 positive cells in human arterial intima and in atherosclerotic lesions. Cardiovasc Res 1995;29:689-96.
28. Hackstein H. Thomson AW. Dendritic cells: emerging pharmacological targets of immunosuppressive drugs. Nat Rev Immunol 2004;4:24-34.
29. Bobryshev YV, Lord RS. Mapping of vascular dendritic cells in atherosclerotic arteries suggests their involvement in local immune-inflammatory reactions. Cardiovasc Res 1998;37:799-810.
30. Aicher A, Heeschen C, Mohaupt M, et al. Nicotine strongly activates dendritic cell-mediated adaptive immunity: potential role for progression of atherosclerotic lesions. Circulation 2003;107:604-11.
31. Alderman CJ, Bunyard PR, Chain BM, et al. Effects of oxidised low density lipoprotein on dendritic cells: a possible immunoregulatory component of the atherogenic micro-environment? Cardiovasc Res 2002;55:806-19.
32. Weis M, Schlichting CL, Engleman EG, et al. Endothelial determinants of dendritic cell adhesion and migration: new implications for vascular diseases. Arterioscler Thromb Vasc Biol 2002;122:1817-23.
33. Sakai A, Kume N, Nishi E, et al. P-selectin and vascular cell adhesion molecule-1 are focally expressed in aortas of hypercholesterolemic rabbits before intimai accumulation of macrophages and T lymphocytes. Arterioscler Thromb Vasc Biol 1997;17:310-6.
34. Davies MJ, Gordon JL, Gearing AJ, et al. The expression of the adhesion molecules ICAM-1, VCAM-1, PECAM, and E-selectin in human atherosclerosis. J Pathol 1993;171:223-9.
35. Ramos CL, Huo Y, Jung U, et al. Direct demonstration of P-selectin-and VCAM-1-dependent mononuclear cell rolling in early atherosclerotic lesions of apolipoprotein E-deficient mice. Circ Res 1999;84:1237-44.
36. Adams DH, Shaw S. Leucocyte-endothelial interactions and regulation of leucocyte migration. Lancet 1994;343:831-6.
37. Wong CW, Christen T, Kwak BR. Connexins in leukocytes: shuttling messages? Cardiovasc Res 2004;62:357-67.
38. Polacek D, Lal R, Volin MV, et al. Gap junctional communication between vascular cells. Induction of connexin43 messenger RNA in macrophage foam cells of atherosclerotic lesions. Am J Pathol 1993;142:593-606.
39. Polacek D, Bech F, McKinsey JF, et al. Connexin43 gene expression in the rabbit arterial wall: effects of hypercholesterolemia, balloon injury and their combination. J Vasc Res 1997;34:19-30.
40. Blackburn JP, Peters NS, Yeh HI, et al. Upregulation of connexin43 gap junctions during early stages of human coronary atherosclerosis. Arterioscler Thromb Vasc Biol 1995;15:1219-28.
41. Kwak BR, Mulhaupt F, Veillard N, et al. Altered pattern of vascular connexin expression in atherosclerotic plaques. Arterioscler Thromb Vasc Biol 2002;22:225-30.
42. Kwak BR, Veillard N, Pelli G, et al. Reduced connexin43 expression inhibits atherosclerotic lesion formation in low-density lipoprotein receptor-deficient mice. Circulation 2003;107:1033-9.
43. Ono SJ, Nakamura T, Miyazaki D, et al. Chemokines: roles in leukocyte development, trafficking, and effector function. J Allergy Clin Immunol 2003;111:1185-99,quiz 1200.
44. Yla-Herttuala S, Lipton BA, Rosenfeld ME, et al. Expression of monocyte chemoattractant protein 1 in macrophage-rich areas of human and rabbit atherosclerotic lesions. Proc Natl Acad Sci U S A 1991;88:5252-6.
45. Takeya M, Yoshimura T, Leonard EJ, et al. Detection of monocyte chemoattractant protein-1 in human atherosclerotic lesions by an anti-monocyte chemoattractant protein-i monoclonal antibody. Hum Pathol 1993;24:534-9.
46. Han KH, Han KO, Green SR, et al. Expression of the monocyte chemoattractant protein-i receptor CCR2 is increased in hypercholesterolemia. Differential effects of plasma lipoproteins on monocyte function. J Lipid Res 1999;40:1053-63.
47. Boring L, Gosling J, Cleary M, et al. Decreased lesion formation in CCR2-/- mice reveals a role for chemokines in the initiation of atherosclerosis. Nature 1998;394:894-7.
48. Gu L, Okada Y, Clinton SK, et al. Absence of monocyte chemoattractant protein-i reduces atherosclerosis in low density lipoprotein receptor-deficient mice. Mol Cell 1998;2:275-81.
49. Gosling J, Slaymaker S, Gu L, et al. MCP-1 deficiency reduces susceptibility to atherosclerosis in mice that overexpress human apolipoprotein B. J Clin Invest 1999;103:773-8.
50. Reape TJ, Groot PH. Chemokines and atherosclerosis. Atherosclerosis 1999;147:213-25.
51. Hayes IM, Jordan NJ, Towers S, et al. Human vascular smooth muscle cells express receptors for CC chemokines. Arterioscler Thromb Vasc Biol 1998;18:397-403.
52. Bjorkerud S. Effects of transforming growth factor-beta 1 on human arterial smooth muscle cells in vitro. Arterioscler Thromb 1991;11:892-902.
53. Grainger DJ, Kemp PR, Witchell CM, et al. Transforming growth factor beta decreases the rate of proliferation of rat vascular smooth muscle cells by extending the G2 phase of the cell cycle and delays the rise in cyclic AMP before entry into M phase. Biochem J 1994;299:227-35.
54. Owens GK, Geisterfer AA, Yang YW, et al. Transforming growth factor-beta-induced growth inhibition and cellular hypertrophy in cultured vascular smooth muscle cells. J Cell Biol 1988;107:771-80.
55. Kojima S, Harpel PC, Rifkin DB. Lipoprotein (a) inhibits the generation of transforming growth factor beta: an endogenous inhibitor of smooth muscle cell migration. J Cell Biol 1991;113:1439-45.
56. Kulkarni AB, Huh CG, Becker D, et al.Transforming growth factor beta 1 null mutation in mice causes excessive inflammatory response and early death. Proc Natl Acad Sci U S A 1993;90:770-4.
57. Shull MM, Ormsby I, Kier AB, et al. Targeted disruption of the mouse transforming growth factor-beta 1 gene results in multifocal inflammatory disease. Nature 1992;359:693-9.
58. Gamble JR, Khew-Goodall Y, Vadas MA. Transforming growth factor-beta inhibits E-selectin expression on human endothelial cells. J Immunol 1993;150:4494-503.
59. Argmann CA, Van Den Diepstraten CH, Sawyez CG, et al. Transforming growth factor-beta1 inhibits macrophage cholesteryl ester accumulation induced by native and oxidized VLDL remnants. Arterioscler Thromb Vasc Biol 2001;21:2011-8.
60. Mallat Z, Tedgui A. The role of transforming growth factor beta in atherosclerosis: novel insights and future perspectives. Curr Opin Lipidol 2002;13:523-9.
61. Gojova A, Brun V, Esposito B, et al. Specific abrogation of transforming growth factor-beta signaling in T cells alters atherosclerotic lesion size and composition in mice. Blood 2003;102:4052-8.
62. Robertson AK, Rudling M, Zhou X, et al. Disruption of TGF-beta signaling in T cells accelerates atherosclerosis. J Clin Invest 2003;112:1342-50.
63. Lutgens E, Daemen MJ. CD40-CD40L interactions in atherosclerosis. Trends Cardiovasc Med 2002;12:27-32.
64. Lutgens E, Gorelik L, Daemen MJ, et al. Requirement for CD154 in the progression of atherosclerosis. Nat Med 1999;5:1313-6.
65. Mach F, Schonbeck U, Sukhova GK, et al. Reduction of atherosclerosis in mice by inhibition of CD40 signalling. Nature 1998;394:200-3.
66. Foy TM, Aruffo A, Bajorath J, et al. Immune regulation by CD40 and its ligand GP39. Annu Rev Immunol 1996;14:591-617.
67. Schonbeck U, Mach F, Libby P. CD154 (CD40 ligand). Int J Biochem Cell Biol 2000;32:687-93.
68. Ridker PM, Hennekens CH, Roitman-Johnson B, et al. Plasma concentration of soluble intercellular adhesion molecule 1 and risks of future myocardial infarction in apparently healthy men. Lancet 1998;351:88-92.
69. Ridker PM, Buring JE, Rifai N. Soluble P-selectin and the risk of future cardiovascular events. Circulation 2001;103:491-5.
70. Ridker PM. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation 2003;107:363-9.
71. Rattazzi M, Puato M, Faggin E, et al. C-reactive protein and interleukin-6 in vascular disease: culprits or passive bystanders? J Hypertens 2003;21:1787-803.
72. Paul A, Ko KW, Li L, et al. C-reactive protein accelerates the progression of atherosclerosis in apolipoprotein E-deficient mice. Circulation 2004;109:647-55.
73. Venugopal SK, Devaraj S, Yuhanna I, et al. Demonstration that C-reactive protein decreases eNOS expression and bioactivity in human aortic endothelial cells. Circulation 2002;106:1439-41.
74. Verma S, Wang CH, Li SH, et al. A self-fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis. Circulation 2002;106:913-9.
75. Verma S, Li SH, Badiwala MV, et al. Endothelin antagonism and interleukin-6 inhibition attenuate the proatherogenic effects of C-reactive protein. Circulation 2002;105:1890-6.
76. Pasceri V, Willerson JT, Yeh ET. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation 2000;102:2165-8.
77. Pasceri V, Cheng JS, Willerson JT, et al. Modulation of C-reactive protein-mediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerosis drugs. Circulation 2001;103:2531-4.
78. Torzewski M, Rist C, Mortensen RF, et al. C-reactive protein in the arterial intima: role of C-reactive protein receptor-dependent monocyte recruitment in atherogenesis. Arterioscler Thromb Vasc Biol 2000;20:2094-9.
79. Zwaka TP, Hombach V, Torzewski J. C-reactive protein-mediated low density lipoprotein uptake by macrophages: implications for atherosclerosis. Circulation 2001;103:1194-7.
80. Wang CH, Li SH, Weisel RD, et al. C-reactive protein upregulates angiotensin type 1 receptors in vascular smooth muscle. Circulation 2003;107:1783-90.
81. Veillard NR, Mach F. Statins: the new aspirin? Cell Mol Life Sci 2002;59:1771-86.
82. Kwak B, Mulhaupt F, Myit S, et al. Statins as a newly recognized type of immunomodulator. Nat Med 2000;6:1399-402.
83. Mulhaupt F, Matter CM, Kwak BR, et al. Statins (HMG-CoA reductase inhibitors) reduce CD40 expression in human vascular cells. Cardiovasc Res 2003;59:755-66.